The use of brachiobasilic arteriovenous fistulae for haemodialysis: a single-centre descriptive study

Cardiovasc J Afr. 2022;33(5):248-253. doi: 10.5830/CVJA-2022-006. Epub 2022 Jun 29.

Abstract

Aim: The main aim of the study was to report on our local experience with the use of brachiobasilic arteriovenous fistulae (BBAVF) and to encourage wider local acceptance of the procedure in accordance with international guidelines. The primary aim was to report on access patency. The secondary aims were to report on functional outcomes and complications.

Methods: This was a retrospective, descriptive study of 41 consecutive haemodialysis patients who underwent BBAVF creation.

Results: The primary patency rates at 30 days, and one and three years were 95.1, 48.8 and 19.5%, respectively. Assisted primary patency rates at 30 days, and one and three years were 100, 67.7 and 24.3%, respectively. Secondary patency rates at 30 days, and one and three years were 100, 70.3 and 27%, respectively.

Conclusion: BBAVF creation can successfully be performed in a resource-constrained environment by surgeons with limited prior experience with the technique. However, careful monitoring, well-established referral pathways for dysfunctional fistulae and access to surgical and endovascular revision seem to be key factors in ensuring long-term patency.

Keywords: arteriovenous; brachiobasilic; fistula; haemodialysis; one‐stage; two‐stage.

MeSH terms

  • Arteriovenous Shunt, Surgical* / adverse effects
  • Arteriovenous Shunt, Surgical* / methods
  • Brachial Artery / diagnostic imaging
  • Brachial Artery / surgery
  • Humans
  • Renal Dialysis / adverse effects
  • Retrospective Studies
  • Treatment Outcome
  • Vascular Patency